Inactive Instrument

Neurotrope, Inc.

Equities

NTRP

US64129T2078

Neurotrope Inc : NTRP The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Neurotrope, Inc. and a Lead Plaintiff Deadline of July 17, 2017

June 29, 2017 at 10:19 am EDT

NEW YORK, NY / ACCESSWIRE / June 29, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ: NTRP) securities between January 7, 2016, and April 28, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing "positive top-line results" of the pivotal Phase 2b trials of Bryostatin-1, noting "improvement in patients with moderate to severe Alzheimer's disease." However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.

If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	20-12-01	CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	20-11-30	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	20-10-06	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-12	CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	20-06-10	CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease	20-05-28	CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction.	20-05-17	CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc.	20-05-16	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-13	CI
Neurotrope, Inc. Announces Board Resignations	20-02-27	CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial	20-01-22	CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope	20-01-22	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Neurotrope Reviews Strategic Alternatives to Maximize Shareholder Value	19-10-08	CI
Neurotrope, Inc. Announces Top-Line Results from Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-09-09	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease	19-07-15	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-09	CI
Neurotrope, Inc. Appoints Michael Ciraolo as General Counsel and Chief Operating Officer	19-04-01	CI
Neurotrope Inc Comments on Biogen's Discontinued Phase 3 Trial in Alzheimer's Disease	19-03-21	CI
Neurotrope Inc. Completes Enrollment of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-03-13	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-08	CI
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute	19-02-04	CI

Chart Neurotrope, Inc.

Duration

Period

More charts

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Sector

More about the company